Clinical Drug Investigation

, Volume 23, Issue 9, pp 615–619 | Cite as

Bilateral Skin Ulceration after Injection of Pegylated Interferon-α-2b in a Patient with Chronic Hepatitis C

  • L. Gallelli
  • V. Guadagnino
  • B. Caroleo
  • N. Marigliano
  • G. B. De Sarro
  • A. Izzi
Case Reports


Sustained Virological Response Pyoderma Gangrenosum Mometasone Erythema Multiforme Skin Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We acknowledge financial support for this study from the Ministero della Salute (Programma di Ricerca Finalizzata anno 2002). The authors have provided no IFNormation on conflicts of interest directly relevant to the content of this study.


  1. 1.
    Carithers Jr RL, Emerson SS. Therapy of hepatitis C: metaanalysis of interferon alfa-2b trials. Hepatology 1997; 26: 83S–8SPubMedCrossRefGoogle Scholar
  2. 2.
    Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology 1997; 26: 96S–100SPubMedCrossRefGoogle Scholar
  3. 3.
    Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547–70PubMedCrossRefGoogle Scholar
  4. 4.
    Poynard T. Effect of pegylated interferon on liver histology. Drug Saf 2002; 2: 14–5Google Scholar
  5. 5.
    Charron A, Bessis D, Dereure O, et al. Local cutaneous side effects of interferons. Presse Med 2001; 30: 1555–60PubMedGoogle Scholar
  6. 6.
    Hadziyannis SJ. Skin diseases associated with hepatitis C virus IFNection. J Eur Acad Dermatol Venereol 1998; 10: 12–21PubMedCrossRefGoogle Scholar
  7. 7.
    Lambert J, Jonlet F, Vanhooteghem O, et al. A non-IFNectious pyodermatitis: Pyoderma gangrenosum. Rev Med Liege 2001; 56: 106–11PubMedGoogle Scholar
  8. 8.
    Guarneri C, Vaccaro M, Cannavo SP, et al. Erythematous-edematous-IFNiltrative plaque on the face: cutaneous angiolupoid leishmaniasis. Eur J Dermatol 2002; 12: 597–9PubMedGoogle Scholar
  9. 9.
    Noblesse I, Beylot-Barry M, Doutre MS, et al. Cutaneous manifestations of rickettsiosis. Ann Dermatol Venereol 2002; 129: 1199–203PubMedGoogle Scholar
  10. 10.
    Cnudde F, Gharakhanian S, Luboinski J, et al. Cutaneous local necrosis following interferon injections [letter]. Int J Dermatol 1991; 30: 147PubMedCrossRefGoogle Scholar
  11. 11.
    Christian MM, Diven DG, Sanchez RL, et al. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. J Am Acad Dermatol 1997; 37: 118–20PubMedCrossRefGoogle Scholar
  12. 12.
    Yang CH, Chen CH, Chan HL. Skin necrosis following a recombinant interferon-beta-1b injection. Chang Gung Med J 2002; 25: 774–7PubMedGoogle Scholar
  13. 13.
    Oh YB, Jun JB, Kim CK, et al. Mixed connective tissue disease associated with skin defects of livedoid vasculitis. Clin Rheumatol 2000; 19: 381–4PubMedCrossRefGoogle Scholar
  14. 14.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30(2): 239–45PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • L. Gallelli
    • 1
  • V. Guadagnino
    • 2
  • B. Caroleo
    • 1
  • N. Marigliano
    • 1
  • G. B. De Sarro
    • 1
  • A. Izzi
    • 2
  1. 1.Chair of Infective Diseases, Department of Experimental and Clinical MedicineUniversity ‘Magna Graecia’ of Catanzaro, Regional Pharmacovigilance Center, ‘Mater Domini’ University HospitalCatanzaroItaly
  2. 2.Chair of Pharmacology, Department of Experimental and Clinical MedicineUniversity ‘Magna Graecia’ of Catanzaro, Regional Pharmacovigilance Center, ‘Mater Domini’ University HospitalCatanzaroItaly

Personalised recommendations